Clinical Trial Update: An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GNR-068, a ustekinumab biosimilar, versus Stelara for moderate-to-severe plaque psoriasis; study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• GNR-068 (ustekinumab)
• Stelara (ustekinumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING